Over the past decade, significant interest has developed for using machine learning in medical devices for assisting in the diagnosis and risk prediction of diseases. Many publications have demonstrated promising preliminary results although the path of deploying a predictive model in the clinic is challenging from a technological and regulatory perspective. This presentation will discuss Nanostics’ work developing ClarityDX Prostate, a medical device which predicts clinically significant prostate cancer, including the challenges of obtaining FDA approval. Training predictive models on large, diverse, clinical datasets is vital for developing trustworthy models although obtaining such datasets can be problematic. Potential solutions for working with large clinical datasets will be discussed.
Liquid biopsy EV analysis with small particle flow cytometry
Extracellular vesicle analysis using “small particle” flow cytometry would be greatly enhanced if data from materials of different refractive index (RI) could be segregated. Likewise, relative sizing of EVs using small particle flow cytometry is confounded by the influence of RI on light scatter. Beads of different composition and refractive index scatter light differently, so that small beads of high RI and large beads of lower RI can have overlapping signals on a two dimension light scatter plot. As particle size decreases, light scatter intensity profiles eventually merge regardless of refractive index. In this project, we aimed to demonstrate graphically, (1) the enhancement of EV flow analysis when using an additional angle of light scatter collection (medium angle of light scatter, MALS) to identify different sample components (e.g. lipids, protein, extracellular vesicles) and (2) the practical reality of sample component overlap at different particle sizes.
Nanostics CSO Desmond Pink will be presenting this work at CYTO 2022, June 3-7, in Philadelphia, US.
CYTO 2022 MOVING FORWARD
Empowering Scientists. Advancing Cytometry.
STARTUP TNT Life Sciences Summit Finale
LIFE SCIENCES SUMMIT FINALE
Date: Thu, March 17, 2022 at 3:30 PM – 7:30 PM MDT
Venue: Online and in-person for more details and to register go to Eventbrite.
CCO Colin Coros will take part in the pre-game show: “Get to Know the Investors, What’s Happening in Life Sciences Anyway, and Why I’m Building It Here”
Invest in the West presented by Amplitude Ventures
Date: Thursday, March 10, 2022
Venue: Virtual – click on the Address button for tickets and agenda
Nanostics COO Catalina Vasquez will be presenting in the Diagnostics, Digital Health, Medical Devices, Technology session. #InvestWest will bring stakeholders in the #lifesciences sector together with investor-ready companies for a day of presentations and valuable discussions.
The Riyadh Global Summit For Artificial Intelligence In Healthcare brought leading AI scientists, Pharma executives, and business leaders from around the world together to explore the potential of AI, machine learning, and deep learning in healthcare. CEO John Lewis spoke on March 5 about AI-Driven Non-Invasive Diagnostic Tests for Cancer and our ClarityDX platform technology.
The Artificial Intelligence in Medicine Student Society (AIMSS) is hosting an in-person/at-home hybrid conference to help inform and educate students on the applications of Artificial Intelligence (AI) and Machine Learning (ML) in the medical field. Dr. Robert Paproski, CTO of Nanostics, will be at the symposium and available to chat about how we use machine learning to diagnose diseases like prostate cancer, bladder cancer, heart disease, and more. Nanostics is proud to be a Silver-level sponsor of this symposium.
Click on the Address Button to learn more and register!